ICA069673
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530943

CAS#: 582323-16-8

Description: ICA069673 is a heteromeric Kv7 channel activator. It is selective for Kv7.2/7.3 over Kv7.3/7.5 (EC50s = 0.69 and 14.3 μM, respectively). ICA-069673 inhibited spontaneous phasic, pharmacologically induced, and nerve-evoked contractions in DSM isolated strips in a concentration-dependent manner. . ICA-069673 decreased the global intracellular Ca(2+) concentration in DSM cells, an effect blocked by the L-type Ca(2+) channel inhibitor nifedipine. ICA-069673 hyperpolarized the membrane potential and inhibited spontaneous action potentials of isolated DSM cells, effects that were blocked in the presence of XE991.


Chemical Structure

img
ICA069673
CAS# 582323-16-8

Theoretical Analysis

MedKoo Cat#: 530943
Name: ICA069673
CAS#: 582323-16-8
Chemical Formula: C11H6ClF2N3O
Exact Mass: 269.0167
Molecular Weight: 269.6358
Elemental Analysis: C, 49.00; H, 2.24; Cl, 13.15; F, 14.09; N, 15.58; O, 5.93

Price and Availability

Size Price Availability Quantity
100.0mg USD 450.0 2 Weeks
200.0mg USD 750.0 2 Weeks
500.0mg USD 1550.0 2 Weeks
1.0g USD 2850.0 2 Weeks
2.0g USD 5150.0 2 Weeks
Bulk inquiry

Synonym: ICA-069673; ICA 069673; ICA069673.

IUPAC/Chemical Name: N-(2-chloro-5-pyrimidinyl)-3,4-difluoro-benzamide

InChi Key: IIBSHMFXVWTQSJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H6ClF2N3O/c12-11-15-4-7(5-16-11)17-10(18)6-1-2-8(13)9(14)3-6/h1-5H,(H,17,18)

SMILES Code: O=C(NC1=CN=C(Cl)N=C1)C2=CC=C(F)C(F)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 269.6358 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Provence A, Malysz J, Petkov GV. The Novel KV7.2/KV7.3 Channel Opener ICA-069673 Reveals Subtype-Specific Functional Roles in Guinea Pig Detrusor Smooth Muscle Excitability and Contractility. J Pharmacol Exp Ther. 2015 Sep;354(3):290-301. doi: 10.1124/jpet.115.225268. Epub 2015 Jun 18. PubMed PMID: 26087697; PubMed Central PMCID: PMC4538873.

2: Vicente-Baz J, Lopez-Garcia JA, Rivera-Arconada I. Effects of novel subtype selective M-current activators on spinal reflexes in vitro: Comparison with retigabine. Neuropharmacology. 2016 Oct;109:131-8. doi: 10.1016/j.neuropharm.2016.05.025. Epub 2016 Jun 2. PubMed PMID: 27263036.

3: Brueggemann LI, Haick JM, Cribbs LL, Byron KL. Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673. Mol Pharmacol. 2014 Sep;86(3):330-41. doi: 10.1124/mol.114.093799. Epub 2014 Jun 18. PubMed PMID: 24944189; PubMed Central PMCID: PMC4152906.

4: Wang AW, Yang R, Kurata HT. Sequence determinants of subtype-specific actions of KCNQ channel openers. J Physiol. 2017 Feb 1;595(3):663-676. doi: 10.1113/JP272762. Epub 2016 Sep 23. PubMed PMID: 27506413; PubMed Central PMCID: PMC5285613.

5: Amato G, Roeloffs R, Rigdon GC, Antonio B, Mersch T, McNaughton-Smith G, Wickenden AD, Fritch P, Suto MJ. N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. ACS Med Chem Lett. 2011 Mar 31;2(6):481-4. doi: 10.1021/ml200053x. eCollection 2011 Jun 9. PubMed PMID: 24900334; PubMed Central PMCID: PMC4018159.

6: Rivera-Arconada I, Vicente-Baz J, Lopez-Garcia JA. Targeting Kv7 channels in pain pathways. Oncotarget. 2017 Feb 21;8(8):12554-12555. doi: 10.18632/oncotarget.15261. PubMed PMID: 28199957; PubMed Central PMCID: PMC5355034.

ICA069673

100.0mg / USD 450.0